BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18093454)

  • 1. Acneiform eruption induced by cetuximab.
    Cotena C; Gisondi P; Colato C; Girolomoni G
    Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Acneiform eruptions induced by cetuximab].
    Walon L; Gilbeau C; Lachapelle JM
    Ann Dermatol Venereol; 2003 Apr; 130(4):443-6. PubMed ID: 12843857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe acneiform eruption induced by cetuximab (Erbitux).
    Lee JE; Lee SJ; Lee HJ; Lee JH; Lee KH
    Yonsei Med J; 2008 Oct; 49(5):851-2. PubMed ID: 18972607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malassezia folliculitis presented as acneiform eruption after cetuximab administration.
    Cholongitas E; Pipili C; Ioannidou D
    J Drugs Dermatol; 2009 Mar; 8(3):274-5. PubMed ID: 19271376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grover's disease induced by cetuximab.
    Tscharner GG; Bühler S; Borner M; Hunziker T
    Dermatology; 2006; 213(1):37-9. PubMed ID: 16778425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab-induced cutaneous toxicity.
    Tomková H; Kohoutek M; Zábojníková M; Pospísková M; Ostrízková L; Gharibyar M
    J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):692-6. PubMed ID: 19925598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cases of acneiform eruption induced by inhibitor of epidermal growth factor receptor.
    Gencoglan G; Ceylan C
    Skin Pharmacol Physiol; 2007; 20(5):260-2. PubMed ID: 17641540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Unilateral acneiform rash in facial palsy].
    Kerob D; Hennequin V; Bousquet G; Behm E; Lebbe C
    Ann Dermatol Venereol; 2010 Nov; 137(11):727-9. PubMed ID: 21074658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
    Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
    J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
    Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
    Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
    Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
    J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosaceiform eruption induced by cetuximab.
    Fernández-Torres R; Martínez Gomez W; Cuevas Santos J; Paradela S; Fonseca Capdevila E
    Eur J Dermatol; 2010; 20(3):392-3. PubMed ID: 20172848
    [No Abstract]   [Full Text] [Related]  

  • 15. Cetuximab-induced acneiform eruption and the response to isotretinoin.
    Vezzoli P; Marzano AV; Onida F; Alessi E; Galassi B; Tomirotti M; Berti E
    Acta Derm Venereol; 2008; 88(1):84-6. PubMed ID: 18176767
    [No Abstract]   [Full Text] [Related]  

  • 16. [Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid].
    Wollenberg A; Moosmann N; Kroth J; Heinemann V; Klein E
    Hautarzt; 2007 Jul; 58(7):615-8. PubMed ID: 17146641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
    de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
    Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - A report of 29 patients.
    Katzer K; Tietze J; Klein E; Heinemann V; Ruzicka T; Wollenberg A
    Eur J Dermatol; 2010; 20(1):82-4. PubMed ID: 19797039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Images in clinical medicine. Cetuximab-associated acneiform eruption.
    Moss JE; Burtness B
    N Engl J Med; 2005 Nov; 353(19):e17. PubMed ID: 16282170
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer].
    Rodríguez-Murphy E; Villanueva-Herraiz S; Ortega-García MP; Pérez-Feliu A; López-Montenegro Soria MA; Camps-Herrero C
    Farm Hosp; 2011; 35(3):114-20. PubMed ID: 21497124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.